4.8 Article

Engineered Cpf1 variants with altered PAM specificities

Journal

NATURE BIOTECHNOLOGY
Volume 35, Issue 8, Pages 789-792

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3900

Keywords

-

Funding

  1. National Institute of General Medical Sciences [T32GM007753]
  2. Paul and Daisy Soros Fellowship
  3. NIH [2 T32 GM 7287-41]
  4. JST, PRESTO [JPMJPR13L8]
  5. JSPS KAKENHI [26291010, 15H01463]
  6. Japan Agency for Medical Research and Development, AMED
  7. Council for Science, and Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology
  8. Karolinska Institutet
  9. Swedish Research Council [521-2014-2866]
  10. Swedish Cancer Research Foundation [CAN 2015/585]
  11. Ragnar Soderberg Foundation
  12. NIH through NIMH [5DP1-MH100706, 1R01-MH110049]
  13. NSF
  14. Howard Hughes Medical Institute
  15. New York Stem Cell Foundation
  16. Simons Foundation
  17. Paul G. Allen Family Foundation
  18. Vallee Foundation
  19. Grants-in-Aid for Scientific Research [17H05592] Funding Source: KAKEN

Ask authors/readers for more resources

The RNA-guided endonuclease Cpf1 is a promising tool for genome editing in eukaryotic cells1-7. However, the utility of the commonly used Acidaminococcus sp. BV3L6 Cpf1 (AsCpf1) and Lachnospiraceae bacterium ND2006 Cpf1 (LbCpf1) is limited by their requirement of a TTTV protospacer adjacent motif (PAM) in the DNA substrate. To address this limitation, we performed a structure-guided mutagenesis screen to increase the targeting range of Cpf1. We engineered two AsCpf1 variants carrying the mutations S542R/K607R and S542R/K548V/N552R, which recognize TYCV and TATV PAMs, respectively, with enhanced activities in vitro and in human cells. Genomewide assessment of off-target activity using BLISS7 indicated that these variants retain high DNA-targeting specificity, which we further improved by introducing an additional non-PAMinteracting mutation. Introducing the identified PAM-interacting mutations at their corresponding positions in LbCpf1 similarly altered its PAM specificity. Together, these variants increase the targeting range of Cpf1 by approximately threefold in human coding sequences to one cleavage site per similar to 11 bp.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available